Myelodysplastic syndrome in children and adolescents

Seminars in Hematology
Charlotte M Niemeyer, Irith Baumann

Abstract

Myelodysplastic syndromes (MDS) are clonal disorders characterized by ineffective hematopoiesis and subsequent frequent development of acute myeloid leukemia (AML). In children and adolescents, MDS are uncommon disorders, accounting for less than 5% of hematopoietic malignancy, with great heterogeneity in presentation and clinical course. The genetic changes predisposing children to MDS are largely obscure. Monosomy 7 is the most common chromosomal abnormality, often occurring as a sole abnormality. The recent pediatric modification of the World Health Organization (WHO) classification has greatly facilitated the diagnostic process. Refractory cytopenia (RC) is the most common MDS subtype in children, occurring in about half of all MDS cases. There is consensus that the relationship between MDS with increased blast count and de novo AML is better defined by biological and clinical features than by blast count. Because monosomy 7 is the only chromosomal abnormality strongly suggestive of MDS, children presenting with a low blast count and other chromosomal aberrations or normal karyotype must be closely observed before a diagnosis of MDS can be established. With an increasing number of children surviving primary cancer with chem...Continue Reading

References

Jul 1, 1993·Stem Cells·A P GillioR J O'Reilly
Jun 24, 1997·Proceedings of the National Academy of Sciences of the United States of America·N ZhaoM M Le Beau
Oct 16, 1999·British Journal of Haematology·H HasleK R Schultz
Dec 10, 1999·Proceedings of the National Academy of Sciences of the United States of America·T TakiY Hayashi
Mar 8, 2000·Cancer Genetics and Cytogenetics·B P AlterM T Elghetany
Oct 29, 2000·British Journal of Haematology·I Dokal
Feb 24, 2001·Journal of Pediatric Hematology/oncology·J M LiptonUNKNOWN Diamond-Black Anemia Registry
May 8, 2001·Medical and Pediatric Oncology·C A Felix
May 8, 2001·Medical and Pediatric Oncology·S M Davies
Sep 7, 2001·Current Opinion in Immunology·A A Aprikyan, D C Dale
Oct 30, 2001·Leukemia·H SasakiUNKNOWN MDS Committee of the Japanese Society of Pediatric Hematology, Japan
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G WoodsBeverly J Lange
Feb 14, 2002·British Journal of Haematology·Akira OharaUNKNOWN Aplastic Anaemia Committee of the Japanese Society of Pediatric Haematology
Mar 6, 2002·Blood·Jens Pedersen-BjergaardClaus Nerlov
Oct 9, 2002·Journal of Pediatric Hematology/oncology·Karen MandelMelvin H Freedman
Oct 24, 2002·Blood·David I KutlerArleen D Auerbach
Dec 24, 2002·Nature Genetics·Graeme R B BoocockJohanna M Rommens
Jun 5, 2003·Nature Genetics·Richard E PersonMarshall Horwitz
Jan 22, 2004·Cancer Genetics and Cytogenetics·Emanuela MaseratiFrancesco Pasquali

❮ Previous
Next ❯

Citations

Dec 19, 2013·Journal of Pediatric Hematology/oncology·Taly GlaubachSeth J Corey
Dec 14, 2011·Hematology·Charlotte M Niemeyer, Irith Baumann
Mar 6, 2009·World Journal of Surgical Oncology·Fadi S FarhatWalid Daya
Apr 12, 2012·Haematologica·Jean DonadieuUNKNOWN Associated investigators of the French Severe Chronic Neutropenia Registry*
Oct 9, 2013·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Carmen M PerrinoAshima Agarwal
Aug 6, 2013·Indian Journal of Pediatrics·Tathagata Chatterjee, V P Choudhry
Jul 28, 2010·Leukemia & Lymphoma·Eliane F RodriguesTeresa De Souza Fernandez
Nov 19, 2013·Pediatric Clinics of North America·Helge D HartungMonica Bessler
Nov 28, 2012·Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)·M GuillénJ Sevilla
Mar 21, 2009·British Journal of Haematology·Doris SteinemannBrigitte Schlegelberger
Nov 16, 2012·Pediatric Blood & Cancer·Angela R SmithMichael R Verneris
Sep 3, 2014·BioMed Research International·Daiane Corrêa de SouzaTeresa de Souza Fernandez
Jul 5, 2015·Mayo Clinic Proceedings·David P Steensma
Jul 23, 2016·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·R Marcos-GrageraR Peris-Bonet
Sep 9, 2016·Pediatric Blood & Cancer·Eliane Ferreira RodriguesTeresa de Souza Fernandez
Aug 26, 2017·Annals of Laboratory Medicine·Gina Zini
Dec 4, 2019·Journal of Pediatric Hematology/oncology·Ann M Mojica, Adam D Wolfe
Jul 17, 2010·Cancer Genetics and Cytogenetics·Libuse LizcovaKyra Michalova

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.